Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a recombinant human platelet-derived growth factor which is indicated for treatment of diabetic foot. It is applied topically.
At the date of the last update, we found no published data on its excretion in breast milk.
Systemic absorption through skin lesion is not significant (Aizpurua 2004, Balfour 1999). Its high molecular weight and minimal systemic absorption makes it unlikely that it will pass into milk in significant amounts.
Due to its protein nature it would be digested and inactivated in the gastrointestinal tract. This low oral bioavailability minimizes the passage into plasma of the infant from ingested breast milk.
It is advisable to wash hands thoroughly and avoid applying it on the breast.